Cancer Chemotherapy and Pharmacology

, Volume 70, Issue 4, pp 523–529 | Cite as

Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer

  • Jae Ho Jeong
  • Min-Hee Ryu
  • Baek-Yeol Ryoo
  • Sung Sook Lee
  • Inkeun Park
  • Sang Hong Lee
  • Kab Choong Kim
  • Jeong Hwan Yook
  • Sung Tae Oh
  • Byung Sik Kim
  • Yoon-Koo Kang
Original Article

Abstract

Background

Adjuvant chemotherapy with S-1 was proven to be effective in Japanese patients with advanced gastric cancer curatively resected with D2 lymph node dissection.

Materials and methods

We retrospectively evaluated the medical records of 305 patients with stage II, III or IV (M0) gastric cancer who had received adjuvant S-1 chemotherapy following curative gastrectomy with D2 lymph node dissection between October 2007 and December 2009. Adjuvant S-1 was administered at a dose of 40 mg/m2 twice daily for 4 weeks followed by 2 weeks of rest, every 6 weeks for eight cycles.

Results

Of the 305 patients, 248 (81.3 %) and 198 (64.9 %) completed four and eight cycles of adjuvant chemotherapy, respectively. The most common reasons for discontinuing treatment prior to the planned eight cycles were adverse events (n = 47, 15.4 %) and tumor recurrence (n = 28, 9.2 %). Sixty-five (21.3 %) patients required dose reduction due to adverse events. The most common grade 3/4 toxicities were neutropenia (n = 39, 12.8 %), diarrhea (n = 15, 4.9 %). Multivariate analysis showed that total gastrectomy [odds ratio (OR) 2.44; 95 % confidence interval (CI) 1.29–4.62, p = 0.006] was an independent risk factor for grade 3/4 hematologic toxicities, and age > 65 years (OR 2.60; 95 % CI 1.34–5.07, p = 0.005) was an independent risk factor for grade 3 non-hematologic toxicities.

Conclusions

Adjuvant chemotherapy with S-1 for 1 year is safe and feasible in Korean patients. Age > 65 years and total gastrectomy are independent risk factors for severe adverse events caused by adjuvant S-1 chemotherapy.

Keywords

Gastric cancer Adjuvant Chemotherapy S-1 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43(1):1–11. doi:10.4143/crt.2011.43.1.1 PubMedCrossRefGoogle Scholar
  3. 3.
    Fuchs CS, Mayer RJ (1995) Gastric carcinoma. N Engl J Med 333(1):32–41. doi:10.1056/NEJM199507063330107 PubMedCrossRefGoogle Scholar
  4. 4.
    Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35(7):1059–1064PubMedCrossRefGoogle Scholar
  5. 5.
    Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 11(7):837–843PubMedCrossRefGoogle Scholar
  6. 6.
    Janunger KG, Hafstrom L, Glimelius B (2002) Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168(11):597–608PubMedCrossRefGoogle Scholar
  7. 7.
    Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88(1):21–27PubMedGoogle Scholar
  8. 8.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730. doi:10.1056/NEJMoa010187 PubMedCrossRefGoogle Scholar
  9. 9.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.1056/NEJMoa055531 PubMedCrossRefGoogle Scholar
  10. 10.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820. doi:10.1056/NEJMoa072252 PubMedCrossRefGoogle Scholar
  11. 11.
    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzen F, Noh SH (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. doi:10.1016/S0140-6736(11)61873-4 PubMedGoogle Scholar
  12. 12.
    Kang Y, Chang H, Zang D, Lee J, Kim T, Yang D, Jang S, Yook J, Oh S, Kim B (2008) Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). J Clin Oncol 26 (May 20 suppl; abstr LBA4511)Google Scholar
  13. 13.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRefGoogle Scholar
  14. 14.
    Pinkel D (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18(7):853–856PubMedGoogle Scholar
  15. 15.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. doi:10.1016/S1053-4296(03)00031-6 PubMedCrossRefGoogle Scholar
  16. 16.
    Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T (2004) Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7(2):104–109. doi:10.1007/s10120-004-0278-3 PubMedCrossRefGoogle Scholar
  17. 17.
    Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A (2011) Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients. Gastric Cancer. doi:10.1007/s10120-011-0068-7 Google Scholar
  18. 18.
    Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, Morita S, Saka M, Katai H, Shimada Y (2011) Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 14(1):28–34. doi:10.1007/s10120-011-0003-y PubMedCrossRefGoogle Scholar
  19. 19.
    Bozzetti F (1992) Total versus subtotal gastrectomy in cancer of the distal stomach: facts and fantasy. Eur J Surg Oncol 18(6):572–579PubMedGoogle Scholar
  20. 20.
    Davies J, Johnston D, Sue-Ling H, Young S, May J, Griffith J, Miller G, Martin I (1998) Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J Surg 22(10):1048–1055PubMedCrossRefGoogle Scholar
  21. 21.
    Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2008) Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemother Pharmacol 61(2):335–343. doi:10.1007/s00280-007-0595-4 PubMedCrossRefGoogle Scholar
  22. 22.
    Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T (2002) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 50(1):25–32. doi:10.1007/s00280-002-0457-z PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jae Ho Jeong
    • 1
  • Min-Hee Ryu
    • 1
  • Baek-Yeol Ryoo
    • 1
  • Sung Sook Lee
    • 1
  • Inkeun Park
    • 1
  • Sang Hong Lee
    • 1
  • Kab Choong Kim
    • 2
  • Jeong Hwan Yook
    • 2
  • Sung Tae Oh
    • 2
  • Byung Sik Kim
    • 2
  • Yoon-Koo Kang
    • 1
  1. 1.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-gu, SeoulKorea
  2. 2.Department of Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-gu, SeoulKorea

Personalised recommendations